1. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with Functional Dyspepsia and Irritable Bowel Syndrome. Gastroenterology 2013; 144: S682 (Mo1881)
  2. Ottillinger B, et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72
  3. Hunt R, Quigley E et al. World Gastroenterology Organisation Global Guidelines: Coping with common GI symptoms in the community.
  4. El-Serag HB, Talley NJ. Systematic review: health related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 387-393
  5. Wagner H. Multitarget therapy - The future of treatment for more than just function dyspepsia. Phytomedicine 2006; 13: SV 122-129
  6. Andersen V, et al. Irritable Bowel Syndrome – The main Recommendations. Clinical Practice Guideline. Deutsches Ärzteblatt International. 2011; 108(44):751-60
  7. Vinson B. Development of Iberogast: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert 2009; pp. 167-189
  8. Saller R, et al. Iberogast: Eine modern phytotherapeutische Arzneimittelkombination zur Behandlung funktioneller Erkrankung des Magen-Darm-Trakts (Dyspepsie, Colon irritabile) – von der Pflanzenheilkunde zur “Evidence Based Phytotherapy” Forsch Komplementärmed Klass Naturheilkd 2002;9(suppl 1):1-20
  9. Kroll U, Cordes C, Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: SV 12-19
  10. Schemann M, Michel K, Hohenester B, Ruhl A. Region-specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-99
  11. Allescher HD. Functional dyspepsia – A multicausal disease and its therapy. Phytomedicine 2006; SV 13: 2-11
  12. Liu CY, Müller MH, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis ME. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-764
  13. Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D. Intestinal spasmolytic effects of STW 5 (Iberogast) and its components. Phytomedicine 2006; 13: SV 75-79
  14. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations. Aliment Pharmacol Ther 2004; 19: 271-279
  15. Nieber K, Michael S, Grotzinger K, Rauwald JW, Kelber O. Anti-inflammatory effect of STW 5, STW 6 and isolated extracts on the rat small intestine. Z Phytotherapie 2008; 29: S29
  16. Melzer J, Rösch W, Reichling J, et al. Metaanalysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279-1287
  17. Kelber O, Gaedcke F, Steinhoff B, Winterhoff H on behalf of the Working Group “Efficacy and Safety” of Kooperation Phytopharmaka, Bonn (Germany). Ethanol in herbal medicinal products in children. Pharm Ind 2008; 70: 1124-1127
  18. Hohenester B, Rühl A, Kelber O, Schemann M. the herbal preparation STW-5 (lberogast®) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 765-773
  19. Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogasts). Phytomedicine 2006; 13: SV 20-35
  20. Iberogast – Scientific summary, Bayer 2019.